Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Item
http://www.wikidata.org/entity/Q42944304
Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose PredictionNo relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled studyLow-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials.Roflumilast: in chronic obstructive pulmonary disease.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseasePharmacokinetic evaluation of roflumilast.Fundamentals of population pharmacokinetic modelling: validation methods.Phosphodiesterase-4 inhibitor therapy for lung diseases.The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
P2860

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Item
http://www.wikidata.org/entity/Q42944304
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Population pharmacokinetic mod ...... codynamic-adverse event model.
@en
Population pharmacokinetic mod ...... codynamic-adverse event model.
@nl
type
label
Population pharmacokinetic mod ...... codynamic-adverse event model.
@en
Population pharmacokinetic mod ...... codynamic-adverse event model.
@nl
prefLabel
Population pharmacokinetic mod ...... codynamic-adverse event model.
@en
Population pharmacokinetic mod ...... codynamic-adverse event model.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P356
P1433
P1476
Population pharmacokinetic mod ...... codynamic-adverse event model.
@en
P2093
P2860
P2888
P304
P31
P356
10.2165/11536600-000000000-00000
P433
P478
P577
P5875
P6179
P698